FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3041725320> ?p ?o ?g. }

• W3041725320 abstract "Introduction Chemotherapy-induced nausea and vomiting (CINV) can be a serious and debilitating adverse effect that is highly feared by cancer patients. For patients receiving moderately emetogenic chemotherapy regimens at our institution in the ambulatory infusion center, palonosetron was selected as the preferred serotonin (5-HT3) antagonist for CINV prophylaxis per the 2016 NCCN Guidelines, when a neurokinin1 antagonist was not included in the prophylactic regimen. The purpose of this study was to evaluate the efficacy of dexamethasone and palonosetron versus granisetron for the prevention of CINV in patients receiving moderately emetogenic chemotherapy regimens. Methods This study is an Institutional Review Board-approved, single-center retrospective review of electronic health records including patients who received moderately emetogenic chemotherapy regimens with CINV prophylaxis with dexamethasone and either palonosetron or granisetron. Results A total of 268 eligible patients were included in the study. Eighty-eight patients received palonosetron and 180 patients received granisetron as their 5-HT3 receptor antagonist between October 31, 2014 and October 31, 2016. There were no statistically significant differences between the two antiemetic groups for the primary outcome of presence of any change in day 1 intravenous prophylactic antiemetics. Nine (10.23%) palonosetron patients and 15 (8.33%) granisetron patients required a change in their day 1 intravenous prophylactic antiemetics ( P = 0.610). Conclusions Despite palonosetron’s better efficacy, longer half-life, and higher binding affinity, the results of this retrospective review demonstrates that the choice of serotonin antagonist, palonosetron or granisetron, did not result in a change in day 1 intravenous prophylactic antiemetics or antiemetic outpatient medications for patients undergoing moderately emetogenic chemotherapy regimens." @default.
• W3041725320 created "2020-07-16" @default.
• W3041725320 creator A5000269944 @default.
• W3041725320 creator A5027418254 @default.
• W3041725320 creator A5041985732 @default.
• W3041725320 creator A5090492181 @default.
• W3041725320 date "2020-07-06" @default.
• W3041725320 modified "2023-09-26" @default.
• W3041725320 title "Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center" @default.
• W3041725320 cites W1932874134 @default.
• W3041725320 cites W1973339347 @default.
• W3041725320 cites W1992358723 @default.
• W3041725320 cites W2020758186 @default.
• W3041725320 cites W2118261787 @default.
• W3041725320 cites W2153494490 @default.
• W3041725320 cites W2155440673 @default.
• W3041725320 cites W2168072459 @default.
• W3041725320 cites W4243894673 @default.
• W3041725320 doi "https://doi.org/10.1177/1078155220938847" @default.
• W3041725320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32633661" @default.
• W3041725320 hasPublicationYear "2020" @default.
• W3041725320 type Work @default.
• W3041725320 sameAs 3041725320 @default.
• W3041725320 citedByCount "2" @default.
• W3041725320 countsByYear W30417253202021 @default.
• W3041725320 countsByYear W30417253202022 @default.
• W3041725320 crossrefType "journal-article" @default.
• W3041725320 hasAuthorship W3041725320A5000269944 @default.
• W3041725320 hasAuthorship W3041725320A5027418254 @default.
• W3041725320 hasAuthorship W3041725320A5041985732 @default.
• W3041725320 hasAuthorship W3041725320A5090492181 @default.
• W3041725320 hasConcept C126322002 @default.
• W3041725320 hasConcept C2776694085 @default.
• W3041725320 hasConcept C2776712918 @default.
• W3041725320 hasConcept C2777452722 @default.
• W3041725320 hasConcept C2779924295 @default.
• W3041725320 hasConcept C2780580376 @default.
• W3041725320 hasConcept C2780852908 @default.
• W3041725320 hasConcept C2780884295 @default.
• W3041725320 hasConcept C2781413609 @default.
• W3041725320 hasConcept C42219234 @default.
• W3041725320 hasConcept C71924100 @default.
• W3041725320 hasConceptScore W3041725320C126322002 @default.
• W3041725320 hasConceptScore W3041725320C2776694085 @default.
• W3041725320 hasConceptScore W3041725320C2776712918 @default.
• W3041725320 hasConceptScore W3041725320C2777452722 @default.
• W3041725320 hasConceptScore W3041725320C2779924295 @default.
• W3041725320 hasConceptScore W3041725320C2780580376 @default.
• W3041725320 hasConceptScore W3041725320C2780852908 @default.
• W3041725320 hasConceptScore W3041725320C2780884295 @default.
• W3041725320 hasConceptScore W3041725320C2781413609 @default.
• W3041725320 hasConceptScore W3041725320C42219234 @default.
• W3041725320 hasConceptScore W3041725320C71924100 @default.
• W3041725320 hasLocation W30417253201 @default.
• W3041725320 hasOpenAccess W3041725320 @default.
• W3041725320 hasPrimaryLocation W30417253201 @default.
• W3041725320 hasRelatedWork W10107969 @default.
• W3041725320 hasRelatedWork W17554371 @default.
• W3041725320 hasRelatedWork W17603007 @default.
• W3041725320 hasRelatedWork W18257812 @default.
• W3041725320 hasRelatedWork W18630196 @default.
• W3041725320 hasRelatedWork W18641483 @default.
• W3041725320 hasRelatedWork W19688590 @default.
• W3041725320 hasRelatedWork W20005634 @default.
• W3041725320 hasRelatedWork W2774690 @default.
• W3041725320 hasRelatedWork W959903 @default.
• W3041725320 isParatext "false" @default.
• W3041725320 isRetracted "false" @default.
• W3041725320 magId "3041725320" @default.
• W3041725320 workType "article" @default.